Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Telix Pharmaceuticals Ltd

Healthcare AU TLX

20.15AUD
-0.9(4.28%)

Last update at 2025-08-01T06:11:00Z

Day Range

19.9821.05
LowHigh

52 Week Range

17.0331.97
LowHigh

Fundamentals

  • Previous Close 21.05
  • Market Cap6922.09M
  • Volume4086903
  • P/E Ratio137.87
  • Dividend Yield-%
  • EBITDA87.58M
  • Revenue TTM783.21M
  • Revenue Per Share TTM2.37
  • Gross Profit TTM 483.95M
  • Diluted EPS TTM0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -98.62200M -80.46500M -47.93500M -31.12200M -15.71389M
Minority interest - - - - -
Net income -104.07900M -80.51000M -44.88700M -27.86700M -13.82982M
Selling general administrative 77.32M 34.92M 18.01M 11.28M 8.50M
Selling and marketing expenses 16.19M 5.89M 1.20M 0.31M 0.58M
Gross profit 94.43M 2.35M 2.66M 0.94M 0.20M
Reconciled depreciation 5.38M 5.17M 4.88M 4.24M 0.00697M
Ebit -92.20600M -75.24700M -46.76000M -28.71400M -15.68487M
Ebitda -86.82700M -70.07300M -41.87800M -24.47800M -15.67791M
Depreciation and amortization 5.38M 5.17M 4.88M 4.24M 0.00697M
Non operating income net other - - - - -
Operating income -92.20600M -75.24700M -46.76000M -28.71400M -27.65396M
Other operating expenses 251.00M 103.70M 54.47M 43.74M -
Interest expense 6.42M 5.22M 1.18M 2.41M 0.03M
Tax provision 5.46M 0.04M -3.04800M -3.25500M -1.88407M
Interest income 0.00100M 0.16M 0.07M 2.39M 1.80M
Net interest income -6.69200M -5.21800M -1.10800M -2.31000M 0.30M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.46M 0.04M -3.04800M -3.25500M -1.88407M
Total revenue 155.98M 4.90M 4.68M 3.48M 0.20M
Total operating expenses 189.44M 101.15M 52.44M 41.20M 27.85M
Cost of revenue 61.56M 2.55M 2.02M 2.54M 0.00000M
Total other income expense net -6.41600M -5.21800M -1.17500M -2.40800M 11.94M
Discontinued operations - - - - -
Net income from continuing ops -104.07900M -80.51000M -44.88700M -27.86700M -13.82982M
Net income applicable to common shares -104.07900M -80.51000M -44.88700M -27.86700M -13.83000M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 1516.43M 398.30M 255.35M 109.81M 157.82M
Intangible assets 309.49M 104.82M 53.47M 51.63M 54.97M
Earning assets - - - - -
Other current assets - 7.10M 6.57M 1.43M 1.79M
Total liab 948.22M 249.39M 175.35M 107.66M 78.81M
Total stockholder equity 568.21M 148.91M 80.01M 2.16M 79.02M
Deferred long term liab - - - - -
Other current liab 85.91M 123.01M 68.11M 6.14M 6.29M
Common stock - 446.27M 370.97M 170.84M 167.06M
Capital stock 0.00000M 446.27M 370.97M 170.84M 167.06M
Retained earnings -212.96200M -263.66500M -272.81500M -173.47100M -92.96100M
Other liab - - 79.98M 67.77M 57.41M
Good will 106.65M 4.85M 5.52M 4.10M 4.22M
Other assets - - 3.97M 0.21M 0.18M
Cash 710.35M 123.24M 116.33M 22.04M 77.94M
Cash and equivalents - - - - -
Total current liabilities 330.91M 157.41M 85.56M 37.98M 19.96M
Current deferred revenue - 112.02M - 19.32M 7.09M
Net debt - -105.79200M -105.88300M -19.49800M -75.73800M
Short term debt - 1.56M 0.64M 0.63M 0.77M
Short long term debt 18.99M 0.96M - 0.02M 0.26M
Short long term debt total - 17.45M 10.45M 2.54M 2.21M
Other stockholder equity - - -0.56200M 4.79M 4.92M
Property plant equipment - - 18.84M 6.33M 4.82M
Total current assets 918.56M 224.85M 173.23M 47.54M 93.63M
Long term investments 6.09M 12.26M - - -
Net tangible assets - - 21.02M -53.57100M 19.83M
Short term investments - - - - -
Net receivables 139.44M 64.78M 39.35M 19.42M 12.40M
Long term debt 551.82M 8.21M 3.31M 0.00000M 0.10M
Inventory 38.14M 17.31M 8.48M 3.45M 0.63M
Accounts payable 68.70M 32.84M 16.81M 11.88M 5.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -33.69200M -18.15000M 4.79M 4.92M
Additional paid in capital - - - - -
Common stock total equity - - - - 167.06M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 74.58M 1.17M 0.33M 0.21M 0.18M
Deferred long term asset charges - - - - -
Non current assets total 597.87M 173.45M 82.12M 62.27M 64.19M
Capital lease obligations 10.64M 8.27M 7.13M 2.52M 1.85M
Long term debt total - - 9.80M 1.91M 1.44M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -135.17300M -25.48900M -16.99700M -2.72600M -1.09100M
Change to liabilities - - 27.64M 4.79M 32.42M
Total cashflows from investing activities -135.17300M -25.48900M -16.99700M -2.72600M -1.09100M
Net borrowings - - 1.74M -0.93600M -0.90400M
Total cash from financing activities 638.92M 10.19M 174.96M 2.85M 34.12M
Change to operating activities - - -3.68600M 2.60M -0.19300M
Net income 49.92M 5.21M -104.07900M -80.51000M -44.88700M
Change in cash 587.11M 6.91M 94.29M -55.90800M 33.35M
Begin period cash flow 123.24M 116.33M 22.04M 77.94M 44.60M
End period cash flow 710.35M 123.24M 116.33M 22.04M 77.94M
Total cash from operating activities 43.03M 23.88M -63.97000M -59.32800M 1.96M
Issuance of capital stock 1.00M 6.65M 181.04M 3.78M 35.15M
Depreciation - 6.92M 5.38M 5.17M 4.88M
Other cashflows from investing activities -34.16900M -1.17100M -2.16300M -1.38700M -0.44700M
Dividends paid - - 168.41M - 34.49M
Change to inventory - -9.63600M -5.02300M -2.82100M -0.09100M
Change to account receivables - -27.38200M -19.93400M -7.19200M -0.32800M
Sale purchase of stock 1.00M 6.65M -7.81600M 3.78M -0.13000M
Other cashflows from financing activities -14.88400M -2.22200M -1.26400M -0.59600M -0.50200M
Change to netincome - - 35.74M 18.64M 10.15M
Capital expenditures 34.03M 10.79M 13.86M 1.34M 0.32M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -64.27100M -57.53400M -1.00700M -2.63000M 31.81M
Stock based compensation - 8.79M 8.11M 1.32M 2.35M
Other non cash items 107.30M 60.50M 41.00M 31.52M 18.66M
Free cash flow 9.00M 13.09M -77.83100M -60.66700M 1.64M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TLX
Telix Pharmaceuticals Ltd		 -0.9 4.28% 20.15 137.87 41.15 8.84 12.40 8.83 74.74
CSL
CSL Ltd		 -6.85 2.53% 264.05 32.71 36.50 8.68 4.61 6.54 20.29
MSB
Mesoblast Ltd		 -0.03 1.26% 2.35 - 454.55 537.04 4.43 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.08% 16.93 15.84 35.21 10.03 5.76 8.78 10.67
CU6
Clarity Pharmaceuticals Ltd		 0.09 2.06% 4.46 - - 131.14 11.00 -0.7791

Reports Covered

Stock Research & News

View All

Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Telix Pharmaceuticals Ltd

55 Flemington Road, North Melbourne, VIC, Australia, 3051

Key Executives

Name Title Year Born
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, Group MD, CEO & Exec. Director 1975
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Director NA
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 1965
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist NA
Ms. Kyahn Williamson Sr. VP of Corp. Communications & Investor Relations NA
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Sr. VP of Global Governance, Risk & Compliance NA
Ms. Lena Moran-Adams Gen. Counsel NA
Ms. Amanda Griffin Communications Mang. NA
Mr. Christian Davis VP Sales and Marketing, EMEA NA
Ms. Meredith Crowe Interim Sr. VP of Global People & Culture NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.